Betul Ersoy-Fazlioglu

This paper identifies FOXJ1 as a mediator of taxane resistance in prostate cancer by regulating microtubule dynamics, with clinical implications for patient stratification.

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.